Log in

Relevant bibliographies by topics / Transcatheter aortic valve implantation (TAVI) / Journal articles

To see the other types of publications on this topic, follow the link: Transcatheter aortic valve implantation (TAVI).

Journal articles on the topic 'Transcatheter aortic valve implantation (TAVI)'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Transcatheter aortic valve implantation (TAVI).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Esposito, Giovanni, and Anna Franzone. "The TAVI: Transcatheter Aortic Valve Implantation." Cardiologia Ambulatoriale, no. 1 (January 30, 2020): 49–57. http://dx.doi.org/10.17473/1971-6818-2020-1-4.

Full text

Abstract:

L’impianto transcatetere di valvola aortica (Transcatheter Aortic Valve Replacement, TAVI) è una procedura di cardiologia interventistica, introdotta nel 2002, che prevede il posizionamento e l’impianto di una protesi biologica a livello dell’annulus aortico mediante accesso percutaneo, prevalentemente transfemorale. Dopo le prime esperienze cliniche, riservate a pazienti senza altre opzioni terapeutiche, la TAVI si è affermata come alternativa all’intervento chirurgico tradizionale di sostituzione valvolare grazie ad una serie di studi randomizzati che ne hanno dimostrato l’efficacia e la sic

APA, Harvard, Vancouver, ISO, and other styles

2

Cook, Selma Tosca, Mario Togni, Patrice Denervaud, and Stephane Cook. "Valve-in-Valve-in-Valve." BMJ Case Reports 17, no. 7 (2024): e260437. http://dx.doi.org/10.1136/bcr-2024-260437.

Full text

Abstract:

In the case of the degeneration of surgical aortic valve replacement (SAVR), the transcatheter aortic valve implantation (TAVI) has become the standard. However, these valves are also susceptible to deterioration. In such instances, a new TAVI implantation may be considered. We present the case of a patient with a SAVR who underwent two TAVI procedures, spaced 8 years apart. We discuss important practical aspects, including the risk of coronary obstruction and the final valve diameter.

APA, Harvard, Vancouver, ISO, and other styles

3

Giuseppe, Bruschi. "Direct Aortic Evolut R Implantation as Valve-In-Valve in a Patient Affected by Leriche Syndrome." Journal of Cardiovascular Medicine and Cardiology 3, no. 1 (2016): 038–40. https://doi.org/10.17352/2455-2976.000030.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is an appropriate therapy to treat elderly patients with severe aortic stenosis considered high-risk surgical candidates. The safety and effectiveness of TAVI have been demonstrated in numerous observational clinical studies, national registries and also in controlled randomized trial [1,2].

APA, Harvard, Vancouver, ISO, and other styles

4

Kleiman, Neal, and Michael J. Reardon. "TAVI: Transcatheter Aortic Valve Implantation." Methodist DeBakey Cardiovascular Journal 7, no. 1 (2011): 49. http://dx.doi.org/10.14797/mdcvj.252.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kleiman, Neal, and Michael J. Reardon. "TAVI: Transcatheter Aortic Valve Implantation." Methodist DeBakey Cardiovascular Journal 7, no. 1 (2011): 49–52. http://dx.doi.org/10.14797/mdcj-7-1-49.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zaman, SM Mustafa, and Chayan Kumar Singha. "Transcatheter Aortic Valve Implantation (TAVI)." University Heart Journal 19, no. 1 (2023): 1–3. http://dx.doi.org/10.3329/uhj.v19i1.69781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rampengan, Starry Homenta, and Jansen Chitrahadinata. "Transcatheter aortic valve implantation: A review article." Bali Medical Journal 11, no. 3 (2022): 1042–48. http://dx.doi.org/10.15562/bmj.v11i3.3571.

Full text

Abstract:

Aortic stenosis is a valvular heart disease commonly found in developed and developing countries. The frequency of aortic valve sclerosis is about 25% in people over 65 years of age. In contrast to developing countries, infectious diseases, such as endocarditis or rheumatic fever, contribute greatly to aortic stenosis. Severe aortic stenosis without valve replacement has a poor prognosis and some patients are at high risk for surgery. Transcatheter aortic valve implantation (TAVI) is emerging as an alternative in patients with aortic stenosis who cannot or are at high risk for surgery. TAVI ha

APA, Harvard, Vancouver, ISO, and other styles

8

Salichkin, D. V., A. E. Komlev, P. M. Lepilin, et al. "Transcatheter aortic valve implantation with commissural alignment." Eurasian heart journal, no. 4 (November 22, 2023): 70–75. http://dx.doi.org/10.38109/2225-1685-2023-4-70-75.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is commonly accepted method of treatment of aortic stenosis in most patients with currently increasing number of TAVI procedures. Patients after TAVI frequently have indications for percutaneous coronary intervention (PCI) that might be technically challenging due to the presence of transcatheter valve. Compromising coronary ostia involves such issues as design of the prosthesis and its position in the aortic root with respect to the commissures of native aortic valve. Since TAVI with commissural alignment can mitigate risk of compromising coronar

APA, Harvard, Vancouver, ISO, and other styles

9

Chiam, Paul TL, Dinesh Nair, Yean Teng Lim, and Cumaraswamy Sivathasan. "Optimising percutaneous valve-in-valve TAVI with bioprosthetic valve fracture." Annals of the Academy of Medicine, Singapore 53, no. 5 (2024): 328–30. http://dx.doi.org/10.47102/annals-acadmedsg.2023413.

Full text

Abstract:

Percutaneous transcatheter aortic valve implantation (TAVI) has become an established therapy for inoperable patients, for high, intermediate and low surgical-risk patients over 65 years old with severe aortic valve stenosis (AS).1,2 Valve-in-valve (ViV) TAVI is an approved indication for patients with degenerated aortic surgical bioprostheses.

APA, Harvard, Vancouver, ISO, and other styles

10

Siontis, George C. M., Pavel Overtchouk, Thomas J. Cahill, et al. "Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis." European Heart Journal 40, no. 38 (2019): 3143–53. http://dx.doi.org/10.1093/eurheartj/ehz275.

Full text

Abstract:

Abstract Aims Owing to new evidence from randomized controlled trials (RCTs) in low-risk patients with severe aortic stenosis, we compared the collective safety and efficacy of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) across the entire spectrum of surgical risk patients. Methods and results The meta-analysis is registered with PROSPERO (CRD42016037273). We identified RCTs comparing TAVI with SAVR in patients with severe aortic stenosis reporting at different follow-up periods. We extracted trial, patient, intervention, and outcome characterist

APA, Harvard, Vancouver, ISO, and other styles

11

Vanhaverbeke, Maarten, Ole De Backer, and Christophe Dubois. "Practical Approach to Transcatheter Aortic Valve Implantation and Bioprosthetic Valve Fracture in a Failed Bioprosthetic Surgical Valve." Journal of Interventional Cardiology 2022 (February 15, 2022): 1–9. http://dx.doi.org/10.1155/2022/9899235.

Full text

Abstract:

Bioprosthetic surgical aortic valve failure requiring reintervention is a frequent clinical problem with event rates up to 20% at 10 years after surgery. Transcatheter aortic valve-in-valve implantation (ViV-TAVI) has become a valuable treatment option for these patients, although it requires careful procedural planning. We here describe and illustrate a stepwise approach to plan and perform ViV-TAVI and discuss preprocedural computerized tomography planning, transcatheter heart valve selection, and implantation techniques. Particular attention is paid to coronary artery protection and the pos

APA, Harvard, Vancouver, ISO, and other styles

12

Ning, Xiaoping, Wei Wang, Fanglin Lu, et al. "Transapical Transcatheter Aortic Valve Implantation for Aortic Regurgitation in Takayasu Arteritis." Heart Surgery Forum 25, no. 5 (2022): E689—E691. http://dx.doi.org/10.1532/hsf.4865.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) has become a popular treatment for surgical high-risk patients with severe aortic stenosis (AS). Recently, we have applied TAVI to the treatment of aortic regurgitation (AR). Compared with conventional surgical procedures, TAVI is less invasive and considered a useful option for these high-risk patients. In this study, we reported a patient who underwent transapical TAVI. The patient was a 52-year-old female with Takayasu arteritis (TA) for 25 years, as well as with severe aortic regurgitation, porcelain aortas, and heart failure. Transapical TAVI

APA, Harvard, Vancouver, ISO, and other styles

13

Dayawansa, Nalin H., Samer Noaman, Lung En Teng, and Nay Min Htun. "Transcatheter Aortic Valve Therapy for Bicuspid Aortic Valve Stenosis." Journal of Cardiovascular Development and Disease 10, no. 10 (2023): 421. http://dx.doi.org/10.3390/jcdd10100421.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) has become first-line treatment for older adults with severe aortic stenosis (AS), however, patients with bicuspid aortic valve (BAV) have been traditionally excluded from randomised trials and guidelines. As familiarity and proficiency of TAVI operators have improved, case-series and observational data have demonstrated the feasibility of successful TAVI in bicuspid aortic valve aortic stenosis (BAV-AS), however, patients with BAV-AS have several distinct characteristics that influence the likelihood of TAVI success. This review aims to summarise

APA, Harvard, Vancouver, ISO, and other styles

14

Penkalla, Adam, Joerg Kempfert, Axel Unbehaun, et al. "Transcatheter Aortic Valve Implantation in Nonagenarians." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 11, no. 6 (2016): 390–95. http://dx.doi.org/10.1097/imi.0000000000000315.

Full text

Abstract:

Objective In this report, we assess the outcome of transcatheter aortic valve implantation (TAVI) in nonagenarians at our institution during a 6-year period. Methods Between April 2008 and July 2014, 40 patients with a mean ± SD age of 91.8 ± 2.3 years (range, 90–98 years) underwent TAVI. Thirty-three patients (82.5%) received transapical TAVI, and seven patients (17.5%) received transfemoral TAVI. Baseline characteristics were as follows: mean ± SD EuroSCORE II, 23.9 ± 14.21; mean ± SD Society of Thoracic Surgeons mortality score, 24.2 ± 11.4; mean ± SD SYNTAX score, 7.6 ± 9.3; mean ± SD NYHA

APA, Harvard, Vancouver, ISO, and other styles

15

ALUR, İhsan, Bekir Serhat YILDIZ, and Yusuf İzzettin ALİHANOĞLU. "Complications of Transcatheter Aortic Valve Implantatiton (TAVI): Letter to the Editor." Turkiye Klinikleri Cardiovascular Sciences 27, no. 3 (2015): 119–20. http://dx.doi.org/10.5336/cardiosci.2016-50396.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Todurov, Mykhailo, Oleh Zelenchuk, Andrii Khokhlov, et al. "Immediate results of transcatheter aortic valve implantation." Polski Merkuriusz Lekarski 52, no. 4 (2024): 400–407. http://dx.doi.org/10.36740/merkur202404103.

Full text

Abstract:

Aim: To assess, analyze and present early postoperative results of transcatheter aortic valve implantation in patients with aortic stenosis. Materials and Methods: During the period from 2017 to 2023, we examined in total 77 patients with severe aortic stenosis and high risk of surgery who were eligible for the TAVI procedure at the “Heart Institute Ministry of Health of Ukraine”. Results: Before implantation, the mean and maximum aortic valve gradients were 53.7±19.1 mm Hg and 90.1±28.8 mm Hg, respectively. The mean and maximum aortic valve gradients after implantation were 9.67±3.18 and 18.7

APA, Harvard, Vancouver, ISO, and other styles

17

Al Ahmad, Judy, and Edward Danson. "Transcatheter Aortic Valve Implantation for Severe Chronic Aortic Regurgitation." Journal of Clinical Medicine 13, no. 10 (2024): 2997. http://dx.doi.org/10.3390/jcm13102997.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) has revolutionised the management of aortic valve disease, offering a less invasive alternative to traditional surgical valve replacement for severe aortic stenosis (AS). TAVI for pure aortic regurgitation (AR) is less well established, and, in fact, it was previously labelled as a relative contraindication. However, TAVI has been utilised for selected cases of pure or predominant AR. The primary limitations regarding the use of TAVI in AR are related to the absence of anatomical factors seen in patients with AS that have contributed to the safe a

APA, Harvard, Vancouver, ISO, and other styles

18

Byczkowska, Katarzyna. "Katz Frailty Syndrom has no Predictive Value in Low-Risk Patients Undergoing Transcatheter Aortic Valve Implantation." Clinical Cardiology and Cardiovascular Interventions 04, no. 16 (2021): 01–08. http://dx.doi.org/10.31579/2641-0419/227.

Full text

Abstract:

Background: Aortic stenosis is a disease of the elderly people, with multiple comorbidities and often with the frailty syndrome. Therefore, we decided that frailty as a clinical factor requires precise characterization as it is a valuable supplement to the risk stratification in transcatheter aortic Valve implantation (TAVI). Objective: The aim of our study was to evaluate the prognostic value of the Katz frailty scale in patients undergoing TAVI in relation to the risk of mortality assessed with the STS scale. Material and methods: The study included 105 patients with severe aortic stenosis (

APA, Harvard, Vancouver, ISO, and other styles

19

Al-Maisary, Sameer, Mina Farag, Willem Hendrik Te Gussinklo, et al. "Are Sutureless and Rapid-Deployment Aortic Valves a Serious Alternative to TA-TAVI? A Matched-Pairs Analysis." Journal of Clinical Medicine 10, no. 14 (2021): 3072. http://dx.doi.org/10.3390/jcm10143072.

Full text

Abstract:

Background: Transcatheter aortic valve implantation is a feasible alternative to conventional aortic valve replacement with expanding indication extending to low-risk patients. Sutureless and rapid-deployment aortic valves were developed to decrease procedural risks in conventional treatment. This paired-match analysis aims to compare patients undergoing surgical transcatheter aortic valve implantation to sutureless and rapid-deployment aortic valve implantation. Methods: Retrospective database analysis between 2010 and 2016 revealed 214 patients undergoing transcatheter aortic valve implantat

APA, Harvard, Vancouver, ISO, and other styles

20

Abdelrahman, Amr, Paul Bamford, Suleman Aktaa, et al. "Transcatheter aortic valve implantation complexity score." Open Heart 12, no. 1 (2025): e002804. https://doi.org/10.1136/openhrt-2024-002804.

Full text

Abstract:

BackgroundIncreasing demand for transcatheter aortic valve implantation (TAVI) places greater emphasis on the efficiency of pathways and services. A significant limitation to increasing TAVI capacity is the availability of cardiac catheterisation laboratory time. We have developed a novel complexity scoring system (TAVI ComplEXity; TEX score) which can aid in planning lists with appropriate case selection. To validate the TEX score, we have undertaken a retrospective analysis of TAVI cases. The hypothesis is that increasing TEX score correlates with increased procedural duration and reduced va

APA, Harvard, Vancouver, ISO, and other styles

21

Tovia-Brodie, Oholi, Yoav Michowitz, and Bernard Belhassen. "Use of Electrophysiological Studies in Transcatheter Aortic Valve Implantation." Arrhythmia & Electrophysiology Review 9, no. 1 (2020): 20–27. http://dx.doi.org/10.15420/aer.2019.38.3.

Full text

Abstract:

New conduction disturbances requiring permanent pacemaker implantation remain common complications following transcatheter aortic valve implantation (TAVI). It has been suggested that electrophysiological studies could help identify patients who will require permanent pacemaker implantation after TAVI. This article summarises contemporary data on the use of electrophysiological studies in patients undergoing TAVI.

APA, Harvard, Vancouver, ISO, and other styles

22

Aktuerk, Dincer, Saeed Mirsadraee, Cesare Quarto, Simon Davies, and Alison Duncan. "Leaflet thrombosis after valve-in-valve transcatheter aortic valve implantation: a case series." European Heart Journal - Case Reports 4, no. 4 (2020): 1–6. http://dx.doi.org/10.1093/ehjcr/ytaa221.

Full text

Abstract:

Abstract Background Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) in degenerated surgical aortic valve replacement (SAVR) is an alternative to redo-SAVR. However, reports on leaflet thrombosis following ViV-TAVI are emerging and subclinical thrombosis has gained recent attention. Although the incidence of transcatheter heart valve (THV) thrombosis after TAVI for native aortic valve disease is low, current imaging studies suggest the incidence of subclinical THV thrombosis may be significantly higher. While anticoagulation strategies for THV patients for native aortic stenos

APA, Harvard, Vancouver, ISO, and other styles

23

Halapas, Antonios, Leonidas Koliastasis, Ioannis Doundoulakis, Christos-Konstantinos Antoniou, Christodoulos Stefanadis, and Dimitrios Tsiachris. "Transcatheter Aortic Valve Implantation and Conduction Disturbances: Focus on Clinical Implications." Journal of Cardiovascular Development and Disease 10, no. 11 (2023): 469. http://dx.doi.org/10.3390/jcdd10110469.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is an established alternative to surgery in patients with symptomatic severe aortic stenosis and has expanded its indications to even low-surgical-risk patients. Conduction abnormalities (CA) and permanent pacemaker (PPM) implantations remain a relatively common finding post TAVI due to the close proximity of the conduction system to the aortic root. New onset left bundle branch block (LBBB) and high-grade atrioventricular block are the most commonly reported CA post TAVI. The overall rate of PPM implantation post TAVI varies and is related to pre

APA, Harvard, Vancouver, ISO, and other styles

24

Emre Ergin, Yunus, Erdal Şimşek, Onur Karahasanoğlu, et al. "[MSB-48] Emergency Surgical Aortic Valve Replacement in Patients Following Failed Valve-in-Valve Transcatheter Valve Procedure: A Case Series." Turkish Journal of Thoracic and Cardiovascular Surgery 32, no. 4 (2024): 73. https://doi.org/10.5606/tgkdc.dergisi.2024.msb-48.

Full text

Abstract:

Valve-in-valve transcatheter aortic valve implantation (TAVI) has become a less invasive alternative to reoperation for elderly or high-risk patients with failed bioprosthetic valves. Data from the EuRECS-TAVI (European Registry on Emergent Cardiac Surgery during TAVI) registry, covering 27,760 TAVI procedures, demonstrated that emergency cardiac surgery due to TAVI complications occurs in 0.76 to 0.98% of cases. The most common reasons include ventricular perforation (28.3%), annular rupture (21.2%), valve migration/embolization (12.7%), and aortic dissection (11.8%).

APA, Harvard, Vancouver, ISO, and other styles

25

Emre Ergin, Yunus, Erdal Şimşek, Onur Karahasanoğlu, et al. "[MSB-48] Emergency Surgical Aortic Valve Replacement in Patients Following Failed Valve-in-Valve Transcatheter Valve Procedure: A Case Series." Cardiovascular Surgery and Interventions 11, no. 100 (2024): 51. https://doi.org/10.5606/e-cvsi.2024.msb-48.

Full text

Abstract:

Valve-in-valve transcatheter aortic valve implantation (TAVI) has become a less invasive alternative to reoperation for elderly or high-risk patients with failed bioprosthetic valves. Data from the EuRECS-TAVI (European Registry on Emergent Cardiac Surgery during TAVI) registry, covering 27,760 TAVI procedures, demonstrated that emergency cardiac surgery due to TAVI complications occurs in 0.76 to 0.98% of cases. The most common reasons include ventricular perforation (28.3%), annular rupture (21.2%), valve migration/embolization (12.7%), and aortic dissection (11.8%).

APA, Harvard, Vancouver, ISO, and other styles

26

Dimitrova, I.N., J. Jorgova, P. Simeonov, H. Angelov, and D. Trendafilova. "TAVI in bicuspid aortic valve." Bulgarian Cardiology 28, no. (2) (2022): 7–18. https://doi.org/10.3897/bgcardio.28.e82418.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is an established choice for the treatment of severe aortic stenosis (AS) in patients who are deemed inoperable or at high surgical risk. There are limited data for the safety and effi cacy of the method in patients with bicuspid aortic valve (BAV), the most common congenital valve defect. Patients with BAV were excluded from randomized clinical trials (RCTs), comparing TAVI to surgery due to the heterogeneous anatomy of this nosological unit and concerns about unsatisfactory procedural and clinical outcomes after TAVI. With the improvement of the

APA, Harvard, Vancouver, ISO, and other styles

27

Harding, Daniel, Thomas J. Cahill, Simon R. Redwood, and Bernard D. Prendergast. "Infective endocarditis complicating transcatheter aortic valve implantation." Heart 106, no. 7 (2020): 493–98. http://dx.doi.org/10.1136/heartjnl-2019-315338.

Full text

Abstract:

Infective endocarditis complicating transcatheter aortic valve implantation (TAVI-IE) is a relatively rare condition with an incidence of 0.2%–3.1% at 1 year post implant. It is frequently caused by Enterococci, Staphylococcus aureus and coagulase negative staphylococci. While the incidence currently appears to be falling, the absolute number of cases is likely to rise substantially as TAVI expands into low risk populations following the publication of the PARTNER 3 and Evolut Low Risk trials. Important risk factors for the development of TAVI-IE include a younger age at implant and significan

APA, Harvard, Vancouver, ISO, and other styles

28

Ya’Qoub, Lina, Jelena Arnautovic, Musa Sharkawi, Mirvat AlAasnag, Hani Jneid, and Islam Y. Elgendy. "Antithrombotic Management for Transcatheter Aortic Valve Implantation." Journal of Clinical Medicine 12, no. 24 (2023): 7632. http://dx.doi.org/10.3390/jcm12247632.

Full text

Abstract:

Background: There have been significant changes in the optimal antithrombotic regimen post TAVI after the results of major clinical trials in the past few years. Given the clinical importance of the optimal antithrombotic therapy post TAVI, we performed a narrative description of the major clinical trials behind the scientific evidence supporting these changes, as well the current guideline recommendations and knowledge gaps. Methods: We performed a narrative description of the major clinical trials behind the scientific evidence supporting these changes. We used PubMed as a major source to co

APA, Harvard, Vancouver, ISO, and other styles

29

Mkrtychev, D. S., A. E. Komlev, A. S. Kolegaev, and T. E. Imaev. "Transcatheter aortic valve implantation in patients with bicuspid aortic valve (literature review)." Siberian Journal of Clinical and Experimental Medicine 39, no. 2 (2024): 28–35. http://dx.doi.org/10.29001/2073-8552-2024-39-2-28-35.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is a technology that allows effective surgical treatment for aortic valve stenosis. One of the causes of aortic stenosis is a congenital pathology characterized by a bicuspidal structure of the aortic valve. This condition has long been considered an absolute contraindication to TAVI, however, the emergence of new generations of prostheses, surgical experience, as well as a deep understanding of the anatomy of bicuspid valves allows to perform TAVI in such patients. This article discusses the existing classifications of bicuspid aortic valves, the

APA, Harvard, Vancouver, ISO, and other styles

30

Chan, Keith Andrew L., Francisco L. Chio, Jeremy Anne A. Alcazar, Carlo Andrew A. Buaya, and Elaine L. Gallardo. "Outcomes of Valve-in-Valve Transcatheter Aortic Valve Implantation Versus Conventional Redo Surgical Aortic Valve Replacement in Patients With Aortic Bioprosthetic Valves: A Meta-analysis." Philippine Journal of Cardiology 48, no. 2 (2020): 36–45. http://dx.doi.org/10.69944/pjc.164f82d17b.

Full text

Abstract:

BACKGROUND: Studies have demonstrated earlier valve degeneration in patients with bioprosthetic aortic valves (AVs), necessitating redo surgical aortic valve replacement (SAVR). Valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) is a novel, off-label technique that offers a feasible alternative to SAVR. OBJECTIVES: The aim of this study was to determine outcomes of patients with bioprosthetic AVs undergoing ViV-TAVI versus redo SAVR, namely, primary clinical outcomes (procedural and 30-day all-cause mortality), secondary clinical outcomes (30-day myocardial infarction, stroke, a

APA, Harvard, Vancouver, ISO, and other styles

31

Stankov, Zoran, Iveta Tasheva, Petar Polomski, et al. "Percutaneous coronary artery intervention after transcatheter aortic valve implantation." Bulgarian Cardiology 27, no. (1) (2021): 66–78. https://doi.org/10.3897/bgcardio.27.e53896.

Full text

Abstract:

Transcatheter implantation of the aortic valve is an increasingly used method for the treatment of aortic stenosis, with a steady trend worldwide to increase the number of TAVI procedures and reduce the age of patients. In Europe, over 180,000 TAVI procedures are currently implemented annually. This review aims to evaluate the patient's prognosis for the different approaches, the technical diffi culties during the procedure, and to offer useful tips for overcoming them. We publish our experience in transcatheter treatment of ischemic heart disease after TAVI implantation.

APA, Harvard, Vancouver, ISO, and other styles

32

Nabil, Naser. "Transcatheter Aortic Valve Implantation Two Decades of Evolution - TAVI From Current Perspective." Acta Informatica Medica 31, no. 4 (2023): 312. http://dx.doi.org/10.5455/msm.2023.35.312-321.

Full text

Abstract:

Background: In the treatment of valvular heart diseases, transcatheter therapies have changed the rules of the game, especially in the case of aortic stenosis and mitral regurgitation. Since the first in man transcatheter aortic valve intervention (TAVI) performed by Dr. Alain Cribier in 2002 in a non-operable aortic stenosis (AS) patient, TAVI has changed the lives of so many patients for whom medical treatment was, up to then, the only option. Objective: This article outlines patient selection and pre-procedure evaluation, current perspectives, recent advances, current and future devices, cu

APA, Harvard, Vancouver, ISO, and other styles

33

Aniss, Seghrouchni, Atmani Noureddine, Moutakiallah Younes, El Bekkali Youssef, and Ait Houssa Mahdi. "Transcatheter Aortic Valve Implantation after Coronary Artery Bypass Graft." RA JOURNAL OF APPLIED RESEARCH 07, no. 10 (2021): 2603–4. https://doi.org/10.47191/rajar/v7i10.14.

Full text

Abstract:

ABSTRACT The perioperative risk of surgical aortic valve replacement in patients with severe aortic stenosis and previous coronary artery bypass grafting (CABG) is increased. Transcatheter aortic valve implantation (TAVI) represents an alternative. We report a case of severe aortic stenosis with an indication for native aortic valve replacement in a patient with prior quadruple bypass surgery. The patient underwent implantation of a 29-mm Corevalve Evolut R aortic valve by left femoral catheterization (TAVI), under general anesthesia with surgical approach to the left scarpa. The procedure wen

APA, Harvard, Vancouver, ISO, and other styles

34

Hayashida, Kentaro. "1. Aortic Valve, 2) Transcatheter Aortic Valve Implantation." Nihon Naika Gakkai Zasshi 105, no. 2 (2016): 215–21. http://dx.doi.org/10.2169/naika.105.215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Salaun, Erwan, Marie-Annick Clavel, Josep Rodés-Cabau, and Philippe Pibarot. "Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation." Heart 104, no. 16 (2018): 1323–32. http://dx.doi.org/10.1136/heartjnl-2017-311582.

Full text

Abstract:

The main limitation of bioprosthetic valves is their limited durability, which exposes the patient to the risk of aortic valve reintervention. Transcatheter aortic valve implantation (TAVI) is considered a reasonable alternative to surgical aortic valve replacement (SAVR) in patients with intermediate or high surgical risk. TAVI is now rapidly expanding towards the lower risk populations. Although the results of midterm durability of the transcatheter bioprostheses are encouraging, their long-term durability remains largely unknown. The objective of this review article is to present the defini

APA, Harvard, Vancouver, ISO, and other styles

36

D'Ancona, Giuseppe, Miralem Pasic, Stephan Dreysse, et al. "Transcatheter Aortic Valve Implantation into a Stentless Prosthetic Valve with a Low Position of the Left Main Coronary Artery." Heart Surgery Forum 15, no. 5 (2012): 268. http://dx.doi.org/10.1532/hsf98.20111174.

Full text

Abstract:

Recently during a transcatheter aortic valve implantation (TAVI), we were faced with a problem that seemed to be untreatable by TAVI. It was difficult to decide whether to perform atypical TAVI or to convert to conventional redo aortic valve surgery in an extremely high-risk patient with a degenerated stentless aortic bioprosthesis.

APA, Harvard, Vancouver, ISO, and other styles

37

Popova, A., D. Trendafilova, J. Jorgova, et al. "Transcatheter aortic valve implantation via transaortic surgical access." Bulgarian Cardiology 28, no. (2) (2022): 123–29. https://doi.org/10.3897/bgcardio.28.e83660.

Full text

Abstract:

We report a case of an 80-years–old patient with a severe, symptomatic aortic valve stenosis and history of ischemic heart disease, previously treated by coronary artery bypass graft surgery. The patient was contraindicated for conventional surgical aortic valve replacement (SAVR) due to advanced age and underlying comorbidity, therefore transcatheter aortic valve implantation (TAVI) has been offered. The access options for the procedure were restricted by the underlying generalized atherosclerosis process causing peripheral vessel disease. We have chosen transaortic access for the patie

APA, Harvard, Vancouver, ISO, and other styles

38

Sarwari, Harun, Andreas Schaefer, Markus J. Barten, and Lenard Conradi. "TAVI Using a Self-Expandable Device for Aortic Regurgitation Following LVAD Implantation." Thoracic and Cardiovascular Surgeon Reports 08, no. 01 (2019): e33-e36. http://dx.doi.org/10.1055/s-0039-1698412.

Full text

Abstract:

Abstract Background In patients treated by left ventricular assist device (LVAD), aortic regurgitation (AR) may occur. Secondary surgery to correct AR is considered high risk. Case Description We report a case of severe AR following LVAD implantation in a patient who was subsequently treated by transcatheter aortic valve implantation (TAVI) using the latest generation self-expandable transcatheter heart valve (THV) (Boston Scientific Acurate neo, size M [Boston Scientific, Marlborough, Massachusetts, United States]). TAVI followed modified procedural protocol and sizing algorithm. THV implanta

APA, Harvard, Vancouver, ISO, and other styles

39

Mylotte, Darren, Ruben LJ Osnabrugge, Giuseppe Martucci, Ruediger Lange, Arie Pieter Kappetein, and Nicolo Piazza. "Adoption of Transcatheter Aortic Valve Implantation in Western Europe." Interventional Cardiology Review 9, no. 1 (2011): 37. http://dx.doi.org/10.15420/icr.2011.9.1.37.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.

APA, Harvard, Vancouver, ISO, and other styles

40

Goltstein, Lia C. M. J., Maxim J. P. Rooijakkers, Naomi D. E. Thierens, et al. "Gastrointestinal Angiodysplasia Resolution After Transcatheter Aortic Valve Implantation." JAMA Network Open 7, no. 10 (2024): e2442324. http://dx.doi.org/10.1001/jamanetworkopen.2024.42324.

Full text

Abstract:

ImportanceHeyde syndrome is the cooccurrence of aortic stenosis and gastrointestinal bleeding secondary to vascular lesions, including angiodysplasias. Several studies have demonstrated cessation of gastrointestinal bleeding after transcatheter aortic valve implantation (TAVI), but the etiology and effects on vascular lesions are largely unknown.ObjectiveTo examine the associations of TAVI with gastrointestinal vascular lesions and identify factors associated with recovery among patients with iron deficiency anemia and severe aortic stenosis.Design, Setting, and ParticipantsIn this prospective

APA, Harvard, Vancouver, ISO, and other styles

41

Sakai, Osamu, Katsuhiko Oka, Tomoya Inoue, and Hitoshi Yaku. "Internal Endoconduit Technique during Transcatheter Aortic Valve Implantation." Thoracic and Cardiovascular Surgeon Reports 08, no. 01 (2019): e5-e7. http://dx.doi.org/10.1055/s-0038-1676963.

Full text

Abstract:

AbstractThe transfemoral approach is the least invasive transcatheter aortic valve implantation (TAVI) approach, but the diameter of the iliofemoral arteries needs to exceed 5 mm. We report a case of limited access transfemoral TAVI by the “internal endoconduit technique,” which is well known as a safe and effective dilatational technique for thoracic endovascular aortic repair. Subsequently, we could deliver the device without iliac artery injury and we performed transfemoral TAVI.

APA, Harvard, Vancouver, ISO, and other styles

42

Lotfi, Shahram, Guido Dohmen, Andreas Götzenich, et al. "Midterm Outcomes after Transcatheter Aortic Valve Implantation." Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 9, no. 5 (2014): 343–48. http://dx.doi.org/10.1097/imi.0000000000000097.

Full text

Abstract:

Objective Transcatheter aortic valve implantation (TAVI) has become a therapeutic option for high-risk or nonoperable patients with severe symptomatic aortic valve stenosis. The best known and most frequently implanted prostheses are the CoreValve and SAPIEN prostheses. We report our experiences and analyze the results of our TAVI program. Methods A total of 357 patients underwent transfemoral (TF) and transapical (TA) TAVI in our center between January 2008 and October 2012. The procedure was performed in 190 patients with CoreValve, in 155 patients with SAPIEN, and in 12 patients with ACURAT

APA, Harvard, Vancouver, ISO, and other styles

43

Watanabe, Yusuke, and Ken Kozuma. "Transcatheter Aortic Valve Implantation for Patients with Smaller Anatomy." Interventional Cardiology Review 10, no. 3 (2015): 155. http://dx.doi.org/10.15420/icr.2015.10.03.155.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) has reached relative maturity for the treatment of severe, symptomatic aortic stenosis (AS). TAVI for patients with smaller anatomy is a challenging procedure due to specific anatomical difficulty and complications including annulus rupture and vascular complications. Prevention of these complications, and the introduction of a newer-generation and lowerprofile TAVI system, will encourage the prevalence of TAVI for patients with smaller anatomy.

APA, Harvard, Vancouver, ISO, and other styles

44

Khawaja, Muzamil, Hafeez Ul Hassan Virk, Dhrubajyoti Bandyopadhyay, et al. "Aortic Stenosis Phenotypes and Precision Transcatheter Aortic Valve Implantation." Journal of Cardiovascular Development and Disease 10, no. 7 (2023): 265. http://dx.doi.org/10.3390/jcdd10070265.

Full text

Abstract:

Patients with a clinical indication for aortic valve replacement can either undergo surgical aortic valve replacement (SAVR) or Transcatheter Aortic Valve Implantation (TAVI). There are many different factors that go into determining which type of replacement to undergo, including age, life expectancy, comorbidities, frailty, and patient preference. While both options offer significant benefits to patients in terms of clinical outcomes and quality of life, there is growing interest in expanding the indications for TAVI due to its minimally invasive approach. However, it is worth noting that th

APA, Harvard, Vancouver, ISO, and other styles

45

Tagliari, Ana Paula, Rodrigo Petersen Saadi, and Eduardo Keller Saadi. "Transcatheter Aortic Valve Implantation for Pure Native Aortic Regurgitation: The Last Frontier." Journal of Clinical Medicine 11, no. 17 (2022): 5181. http://dx.doi.org/10.3390/jcm11175181.

Full text

Abstract:

Transcatheter aortic valve implantation (TAVI) to treat patients with severe symptomatic aortic stenosis is a well-established procedure. Even though cases series have reported TAVI use in high-risk patients with pure native aortic regurgitation, this is still considered an off-label intervention, especially when the aortic annulus dimensions are beyond the recommended by prosthesis manufacturers. Herein, we provide an updated review regarding the transcatheter treatment of pure native aortic regurgitation and illustrate this issue by presenting a clinical case of a patient with pure aortic re

APA, Harvard, Vancouver, ISO, and other styles

46

Russo, Eleonora, Domenico R. Potenza, Michela Casella, et al. "Rate and Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation: Current Status." Current Cardiology Reviews 15, no. 3 (2019): 205–18. http://dx.doi.org/10.2174/1573403x15666181205105821.

Full text

Abstract:

Transcather aortic valve implantation (TAVI) has become a safe and indispensable treatment option for patients with severe symptomatic aortic stenosis who are at high surgical risk. Recently, outcomes after TAVI have improved significantly and TAVI has emerged as a qualified alternative to surgical aortic valve replacement in the treatment of intermediate risk patients and greater adoption of this procedure is to be expected in a wider patients population, including younger patients and low surgical risk patients. However since the aortic valve has close spatial proximity to the conduction sys

APA, Harvard, Vancouver, ISO, and other styles

47

Kremneva, L. V., L. I. Gapon, S. V. Shalaev, and D. V. Krasheninin. "Acute Kidney Injury after Transcatheter Aortic Valve Implantation." Rational Pharmacotherapy in Cardiology 18, no. 3 (2022): 261–67. http://dx.doi.org/10.20996/1819-6446-2022-06-10.

Full text

Abstract:

Aim. The aim of the study was to evaluate the incidence and predictors of acute kidney injury (AKI) associated with transcatheter aortic valve implantation (TAVI).Material and methods. 50 patients (39 women, 11 men) aged 76 (71; 80) years who underwent TAVI were examined. One day after TAVI, blood creatinine level was determined by the Jaffe method and troponin I by a highly sensitive method (hs-cTnI). Acute kidney injury (AKI) was diagnosed according to the KDIGO criteria (2012). The following hospital complications were evaluated: cases of cardiac death, intraoperative myocardial infarction

APA, Harvard, Vancouver, ISO, and other styles

48

Nikas, Dimitrios, Lampros Lakkas, Katerina Naka, and Lampros Michalis. "Transcatheter Aortic Valve Implantation (TAVI) in Bicuspid Anatomy." Journal of Clinical Medicine 14, no. 3 (2025): 772. https://doi.org/10.3390/jcm14030772.

Full text

Abstract:

Bicuspid aortic valve (BAV) stenosis, a common congenital condition, presents unique challenges for transcatheter aortic valve replacement (TAVI) due to anatomical variations like cusp morphology, coexisting aortopathy and calcification. TAVI offers a viable option for BAV patients with refinements in technique and technology, though ongoing research is essential to optimize patient-specific approaches and long-term results. Key considerations for TAVI in BAV include precise valve sizing, positioning, and the need for rigorous pre-procedural imaging to mitigate risks such as paravalvular leak

APA, Harvard, Vancouver, ISO, and other styles

49

Martins, Ana Margarida, Maria Lurdes Castro, and Isabel Fragata. "Experiência Inicial de um Programa de TAVI: Análise da Decisão Anestésica e sua Evolução." Acta Médica Portuguesa 32, no. 2 (2019): 126. http://dx.doi.org/10.20344/amp.10982.

Full text

Abstract:

Introduction: Transcatheter aortic valve implantation is a less invasive option for aortic valve replacement. The number of transcatheter aortic valve implantations under local anesthesia with sedation has been increasing as the team’s experience increases and less invasive accesses are used. The aim of this study is to describe the evolution of the anesthetic technique in patients undergoing transcatheter aortic valve implantation at our center over the years, as which was compared. Material and Methods: Retrospective study in 149 consecutive patients undergoing transcatheter aortic valve imp

APA, Harvard, Vancouver, ISO, and other styles

50

Chung, Robin. "Transcatheter Aortic Valve Implantation (TAVI) for Aortic Stenosis." International Cardiovascular Forum Journal 1, no. 2 (2015): 62. http://dx.doi.org/10.17987/icfj.v1i2.22.

Full text

Abstract:

Aortic stenosis remains the commonest form of valve disease in<br />modern cardiology. With fifty years’ experience, surgical valve<br />replacement remains the gold standard treatment for survival<br />benefit, durability and symptomatic relief. Percutaneous<br />transcatheter aortic valve replacement has recently gained a<br />credible momentum for inoperable and very high risk patients<br />with severe aortic stenosis. Early and medium term results<br />have demonstrated a proven survival benefit over conservative<br />management, with documen

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!